United Kingdom

People: Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

23 Apr 2019
Change (% chg)

$-0.37 (-2.54%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Satvat, Ali 

Mr. Ali J. Satvat is Independent Director of the Coherus BioSciences, Inc. Mr. Satvat joined KKR in January 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat has also served as a member of the boards of directors of publicly held PRA Health Sciences since September 2013 and several privately held organizations, including AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Cohera Medical, Slayback Pharma and Trilogy MedWaste. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012 and was actively involved with many of the firm’s successful private equity and growth equity investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B. in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat also serves on the board of directors of the Healthcare Private Equity Association.

Basic Compensation

Total Annual Compensation, USD 53,750
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 317,532
Fiscal Year Total, USD 371,282

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Dennis Lanfear


Jean-Frederic Viret


Peter Watler


Alan Herman


Vincent Anicetti


Barbara Finck

As Of  31 Dec 2017